

In a mouse study, it was shown that the mitochondrial antioxidant MitoQ, which is sold as a dietary supplement, can counteract the negative effects that HIV and antiretroviral therapy (ART) have on the mitochondria in the brain, heart, aorta, lungs, kidney, and liver.
The ratio of nuclear DNA (ntDNA) to mitochondrial DNA (mtDNA) in humans and mice was calculated using a molecular technique as a marker of mitochondrial dysfunction. This ratio’s decline indicates a mitochondrial malfunction.
HIV-infected mice receiving ART showed mitochondrial dysfunction in the human immune cells in the brain, heart, liver, lungs, and gut compared to uninfected mice. In mouse heart cells, mitochondrial function was likewise impacted by ART.
Compared to HIV-infected mice on ART, those treated with MitoQ for 90 days had less mitochondrial dysfunction in their organs.
The major cellular components known as mitochondria are crucial for the efficient operation of organs like the brain, heart, liver, and kidney. Chronic immunological dysfunction and inflammation brought on by HIV contribute to organ damage. Although the causes of this are unknown, it is known that mitochondrial dysfunction, which is present in chronic HIV, contributes to organ damage. HIV-related illnesses that impact organs like the liver, heart, and brain do not have any treatments available.
Humanized mice were utilized by the researchers because they have human immune cells that are susceptible to HIV infection.
They gave them the virus, treated them with ART using emtricitabine, raltegravir, and tenofovir disoproxil fumarate, and then gave them MitoQ through their water for three months. MitoQ wasn’t administered to the control mice.
The scientists point out that humanized mice do not precisely mimic human HIV infection. Furthermore, because the infected mice were exposed to both the virus and the ART, it was impossible to determine how much, exactly, the virus vs the ART contributed to mitochondrial dysfunction in human cells.
These preliminary results might be the basis for HIV-positive human clinical trials.
“MitoQ is a diet supplement that is known to be safe in humans and is readily available for use,” said senior author Dr. Theodoros Kelesidis, associate professor of medicine in the division of infectious diseases at the David Geffen School of Medicine at UCLA.
Our findings support clinical trials of MitoQ in people with HIV who take antiretrovirals to determine whether it can be a potential treatment for comorbidities associated with chronic HIV infection. Until then people with HIV should not take this diet supplement for treatment of any conditions associated with HIV infection.”
The study is published in the Journal of Infectious Diseases.
more recommended stories
Scientists Unveil Next-Gen Eye-Tracking with Unmatched Precision
Eye-tracking technology has long been a.
New Study Questions Fluid Restriction in Heart Failure Management
A groundbreaking study presented at the.
Role of Leptin Signaling in the DMH for Metabolic Regulation
A groundbreaking study from the Pennington.
COVID-19 Vaccines May Lower the Risk of Long COVID by 27%
A recent rapid review suggests that.
3D-Printed Hydrogel for Meniscus Tear Treatment
Meniscus tears are one of the.
Machine Learning Predicts Early Mortality in IBD Patients
A groundbreaking study published in the.
Endometriosis Treatment Advances: Latest Research and Therapy
Recent endometriosis treatment advances are reshaping.
Lung Cancer Screening Gaps Persist Despite Updated Guidelines
A recent study led by researchers.
Altered Knee Movement After ACL Surgery May Trigger Early Osteoarthritis
A recent study published in the.
BRP Peptide for Weight Loss: A Natural Alternative to Ozempic?
The rising obesity epidemic has fueled.
Leave a Comment